Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study.
Antineutrophil cytoplasmic antibodies
Relapse
Vasculitis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
30
05
2019
accepted:
10
10
2019
revised:
30
09
2019
pubmed:
8
1
2020
medline:
2
2
2021
entrez:
8
1
2020
Statut:
ppublish
Résumé
To investigate the activity of relapsing events (RE) and their mode of presentation in patients with anti-neutrophil cytoplasmic (ANCA)-associated vasculitis (AAV). Patients diagnosed with AAV between 1990 and 2015 experiencing at least one RE were investigated. The different organ involvements were registered during each RE. Presentation at initial onset (IO) and RE were compared. The Birmingham Vasculitis Activity Score was used to assess the activity. Ninety-nine patients were followed: 54 patients with 96 RE and 45 patients with none. The rate of RE was 53% with a median time of follow-up of 6.8 years. The mean time to first RE was 2.8 years. Thirty patients experienced one single RE, 15 had 2, 5 had 3, 2 had 4, and 2 had, respectively, 7 and 8. Fifty-five percent of RE had the same features as IO. Compared to IO, some clinical manifestations were less present: constitutional symptoms (29% vs 69%), ear-nose-throat (50% vs 76%), lung involvement (59% vs 76%), peripheral neuropathies (14% vs 24%), arthritis (7% vs 27%), kidney (25% vs 41%), and heart (4% vs 20%) (p < 0.001). Skin, eye, and bowel manifestations were not significantly less involved during RE. The mean Birmingham Vasculitis Activity Score at IO was 9.02 and 5.11 at relapse (p < 0.0001). Among the 96 RE, 46% had a new organ involvement compared to IO: none were life-threatening. Global activity of RE in AAV patients is lower than that of IO. Fewer organs are involved in relapses. RE turned out to begin with the same manifestations as IO in most cases.Key Points•First study looking into clinical characteristics of relapses including mostly granulomatosis with polyangiitis.•Around half of patients with AAV seemed to relapse in a similar way compared to the initial diagnosis.•The activity score during relapsing events is less important.
Identifiants
pubmed: 31907693
doi: 10.1007/s10067-019-04816-7
pii: 10.1007/s10067-019-04816-7
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1601-1608Références
Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494
pubmed: 21109517
doi: 10.1136/ard.2010.137778
Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D, European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548
pubmed: 21953279
doi: 10.1002/art.33361
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232
pubmed: 20647199
pmcid: 3137658
doi: 10.1056/NEJMoa0909905
Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U, RAVE-ITN Research Group (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75:1166–1169
pubmed: 26621483
doi: 10.1136/annrheumdis-2015-208073
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody–associated vasculitis treated with glucocorticoids. Arthritis Rheum 67:1629–1636
doi: 10.1002/art.39104
Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908–2918
pubmed: 18759282
pmcid: 2754705
doi: 10.1002/art.23800
Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12–17
pubmed: 8250451
doi: 10.7326/0003-4819-120-1-199401010-00003
McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH (2012) Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7:240–247
pubmed: 22134625
pmcid: 3280023
doi: 10.2215/CJN.05610611
Tan JA, Choi HK, Xie H, Sayre EC, Esdaile JM, Aviña-Zubieta JA (2019) All-cause and cause-specific mortality in patients with granulomatosis with polyangiitis: a population-based study. Arthritis Care Res 71:155–163
doi: 10.1002/acr.23587
Rahmattulla C, Berden AE, Wakker S-C, Reinders MEJ, Hagen EC, Wolterbeek R et al (2015) Incidence of malignancies in patients with antineutrophil cytoplasmic antibody–associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheum 67:3270–3278
doi: 10.1002/art.39317
Royer M, Cervera P, Kahan A, Menkès C-J, Puéchal X (2013) Mucormycosis cerebral arteritis mimicking a flare in ANCA-associated vasculitis. Lancet Infect Dis 13:182
pubmed: 23347635
doi: 10.1016/S1473-3099(12)70143-3
Chen M, Yu F, Zhao M-H (2008) Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. J Rheumatol 35:448–450
pubmed: 18085730
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107
pubmed: 2202308
doi: 10.1002/art.1780330807
Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100
pubmed: 2202307
doi: 10.1002/art.1780330806
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11
pubmed: 23045170
doi: 10.1002/art.37715
Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227
pubmed: 16901958
doi: 10.1136/ard.2006.054593
Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune J, St Clair EW, Luqmani RA, International Network for the Study of the Systemic Vasculitides (INSSYS) (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:912–920
pubmed: 11318006
doi: 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68:1827–1832
pubmed: 19054820
doi: 10.1136/ard.2008.101279
Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617
pubmed: 17170053
doi: 10.1136/ard.2006.062711
Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatol Oxf Engl 49:2181–2190
doi: 10.1093/rheumatology/keq244
Cao Y, Tian Z, Li W, Ma L, Yu Y, Ren W (2014) Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease. J Rheumatol 41:916–922
pubmed: 24634200
doi: 10.3899/jrheum.130758
Li Z-Y, Chang D-Y, Zhao M-H, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol Hoboken NJ 66:1920–1926
doi: 10.1002/art.38621
Lega J-C, Seror R, Fassier T, Aumaître O, Quere I, Pourrat J, Gilson B, Sparsa A, Wahl D, le Jeunne C, Decaux O, Mouthon L, Mahr A, Cohen P, Guillevin L, Pagnoux C, French Vasculitis Study Group (FVSG) (2014) Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. Semin Arthritis Rheum 43:681–688
pubmed: 24120178
doi: 10.1016/j.semarthrit.2013.09.001
Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, Limburg PC, Tervaert JW (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033
pubmed: 11014352
doi: 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O
Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR et al (2016) Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol Hoboken NJ 68:1700–1710
doi: 10.1002/art.39637
Koh JH, Kemna MJ, Cohen Tervaert JW, Kim W-U (2016) Editorial: Can an increase in antineutrophil cytoplasmic autoantibody titer predict relapses in antineutrophil cytoplasmic antibody–associated vasculitis? Arthritis Rheum 68:1571–1573
doi: 10.1002/art.39639
Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA (2012) Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatol Oxf Engl 51:100–109
doi: 10.1093/rheumatology/ker280
Riding AM, D’Cruz DP (2010) A case of mistaken identity: subacute bacterial endocarditis associated with p-antineutrophil cytoplasmic antibody. BMJ Case Rep 2010
Uh M, McCormick IA, Kelsall JT (2011) Positive cytoplasmic antineutrophil cytoplasmic antigen with PR3 specificity glomerulonephritis in a patient with subacute bacterial endocarditis. J Rheumatol 38:1527–1528
pubmed: 21724732
doi: 10.3899/jrheum.101322
Langlois V, Lesourd A, Girszyn N, Ménard J-F, Levesque H, Caron F et al (2016) Antineutrophil cytoplasmic antibodies associated with infective endocarditis. Medicine (Baltimore) 95:e2564
doi: 10.1097/MD.0000000000002564
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780
pubmed: 25372085
doi: 10.1056/NEJMoa1404231